Expert Review of Neurotherapeutics最新文献_第4页

A status update on the unkept promise of high-frequency spinal cord stimulation for treatment-refractory chronic migraine. 高频脊髓刺激治疗难治性慢性偏头痛的最新进展。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-08-19 DOI: 10.1080/14737175.2026.2718402

Paolo Martelletti, Claudio Tana

{"title":"A status update on the unkept promise of high-frequency spinal cord stimulation for treatment-refractory chronic migraine.","authors":"Paolo Martelletti, Claudio Tana","doi":"10.1080/14737175.2026.2718402","DOIUrl":"10.1080/14737175.2026.2718402","url":null,"abstract":"Introduction: Chronic migraine (CM) refractory to conventional pharmacotherapy (r-CM) remains a debilitating neurological condition with limited therapeutic options. High-frequency spinal cord stimulation at 10 kilohertz (HF-SCS) has recently emerged as a distinct neuromodulatory paradigm for this patient population. Unlike traditional spinal cord stimulation, HF-SCS operates above the frequency range that generates paresthesia, thereby eliminating stimulation-induced sensation while potentially engaging unique analgesic mechanisms.Areas covered: This focused narrative review synthesizes the available clinical evidence, technical considerations, and mechanistic hypotheses specifically pertaining to cervical HF-SCS for refractory chronic migraine (r-CM). The authors further provide their expert perspectives on the future of this technology as a treatment option for refractory chronic migraine.Expert opinion: Current data from prospective open-label studies and retrospective case series suggest that cervical HF-SCS may reduce monthly migraine days, facilitate conversion from chronic to episodic migraine patterns in some implanted patients, and may improve headache-related disability and quality of life over at least 52 weeks of follow-up. The paresthesia-free nature of HF-SCS confers a distinct advantage for both patient tolerability and future trial design, as it permits sham-controlled methodologies that have historically been impossible with conventional neurostimulation. However, these findings remain preliminary and should be considered hypothesis-generating pending confirmation in adequately powered randomized sham-controlled trials.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"873-880"},"PeriodicalIF":4.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovation is not enough: lessons from lasmiditan for real-world effectiveness in acute migraine therapy. 创新是不够的：拉斯米坦在急性偏头痛治疗中的实际有效性的经验。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-07-10 DOI: 10.1080/14737175.2026.2701917

Simona Guerzoni, Lanfranco Pellesi

引用次数: 0

Correction. 修正。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-01-19 DOI: 10.1080/14737175.2026.2618409

引用次数: 0

Can the integration of blood-based biomarkers into Alzheimer's disease diagnosis revolutionize the field? 将基于血液的生物标志物整合到阿尔茨海默病的诊断中，能给该领域带来革命性的变化吗？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-07-07 DOI: 10.1080/14737175.2026.2700246

Lorenzo Gaetani, Giovanna Nardi, Lucilla Parnetti

{"title":"Can the integration of blood-based biomarkers into Alzheimer's disease diagnosis revolutionize the field?","authors":"Lorenzo Gaetani, Giovanna Nardi, Lucilla Parnetti","doi":"10.1080/14737175.2026.2700246","DOIUrl":"10.1080/14737175.2026.2700246","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is a clinical-biological entity in which pathophysiological changes precede symptoms by years. Biomarkers are essential for early and accurate diagnosis, particularly in the era of disease-modifying therapies requiring biological confirmation. Cerebrospinal fluid (CSF) and amyloid positron emission tomography (amyloid-PET) are the reference standards, but increasing attention is devoted to blood-based biomarkers (BBMs) due to their scalability and cost-effectiveness.Areas covered: In this critical perspective, the authors critically appraise the current evidence supporting plasma phosphorylated tau at threonine 217 (p-tau217) as the leading BBM for AD. They also discuss its analytical performance, biological rationale, and diagnostic accuracy across the AD continuum, its relationship with established CSF, PET, and neuropathological biomarkers, its potential role in identifying patients eligible for disease-modifying therapies, and the main clinical and biological factors influencing its interpretation. Finally, they highlight current limitations, unresolved challenges, and give their future perspectives for the integration of plasma biomarkers into routine clinical practice.Expert opinion: BBMs are expected to reshape AD diagnostics. A stepwise approach, using plasma biomarkers as first-line tests followed by confirmatory CSF or PET, is currently the most feasible strategy. Ultimately, highly specific, brain-derived tau biomarkers may enable BBMs to replace CSF biomarkers.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"839-852"},"PeriodicalIF":4.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of current and emerging strategies for phantom limb pain. 幻肢痛的当前和新兴策略概述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-07-27 DOI: 10.1080/14737175.2026.2709803

Marco Cascella, Matteo De Simone, Alessandro Vittori, Stefano Fasolino, Giorgio Iaconetta

{"title":"An overview of current and emerging strategies for phantom limb pain.","authors":"Marco Cascella, Matteo De Simone, Alessandro Vittori, Stefano Fasolino, Giorgio Iaconetta","doi":"10.1080/14737175.2026.2709803","DOIUrl":"10.1080/14737175.2026.2709803","url":null,"abstract":"Introduction: Phantom limb pain (PLP) is a disabling neuropathic pain syndrome affecting many individuals following limb amputation. Despite decades of research, PLP management remains challenging because of its complex and incompletely understood pathophysiology.Areas covered: According to the SANRA recommendations, this updated narrative review provides a critical overview of current pathophysiological concepts and clinically relevant established and emerging therapeutic strategies for PLP. Relevant literature was identified through searches of PubMed/MEDLINE, Scopus, and Web of Science databases using predefined combinations of terms related to PLP. The review integrates evidence from pharmacological studies, rehabilitation trials, neuromodulation research, and emerging digital-health applications.Expert opinion: PLP should be considered a biologically heterogeneous pain condition associated with multiple potential mechanisms, including peripheral, spinal, central, and psychosocial factors. Current evidence suggests that the relative contribution of these mechanisms varies across individuals, and no single mechanism adequately explains all cases of PLP. Conventional pharmacological strategies provide limited and inconsistent benefit, whereas multimodal interventions combining sensorimotor rehabilitation, neuromodulation, psychological support, and targeted surgical approaches are promising. Future progress will likely depend on mechanism-based phenotyping, integration of artificial intelligence, brain-computer interfaces, and closed-loop neuromodulation systems to enable personalized management strategies. However, high-quality studies with standardized outcome measures and long-term assessments are urgently needed.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"895-905"},"PeriodicalIF":4.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the genetic risk of schizophrenia. 了解精神分裂症的遗传风险。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-07-13 DOI: 10.1080/14737175.2026.2702634

Sophie L Chick, Elliott Rees

引用次数: 0

Profiling intranasal esketamine for adults with major depressive disorder and acute suicidal ideation or behavior: a phenotype-informed drug profile. 重度抑郁症和急性自杀意念或行为的成人鼻用艾氯胺酮分析：一种表型知情的药物概况。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-08-18 DOI: 10.1080/14737175.2026.2714839

Mario Pinzi, Alessandro Cuomo, Maria Beatrice Rescalli, Caterina Pierini, Andrea Fagiolini

{"title":"Profiling intranasal esketamine for adults with major depressive disorder and acute suicidal ideation or behavior: a phenotype-informed drug profile.","authors":"Mario Pinzi, Alessandro Cuomo, Maria Beatrice Rescalli, Caterina Pierini, Andrea Fagiolini","doi":"10.1080/14737175.2026.2714839","DOIUrl":"10.1080/14737175.2026.2714839","url":null,"abstract":"Introduction: Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists. Intranasal esketamine, a rapid-acting N-methyl-D-aspartate receptor antagonist, is approved for MDD with acute suicidal ideation or behavior in the United States and for rapid reduction of depressive symptoms constituting a psychiatric emergency in Europe.Areas covered: This Drug Profile reviews the pharmacology, pharmacokinetics, efficacy, safety, and regulatory positioning of intranasal esketamine, with attention to heterogeneity in suicidal presentations. Literature was identified through targeted PubMed/MEDLINE and Embase searches from inception to February 2026, supplemented by regulatory documents and reference-list hand-searching.Expert opinion: The pivotal ASPIRE trials showed rapid improvement in depressive symptom burden but no significant separation from placebo on the suicidality-specific CGI-SS-r endpoint. Reductions in hopelessness, psychological pain, or cognitive constriction are plausible but unproven as phenotype-specific effects. Esketamine should be used within its regulatory indication as one component of supervised, multimodal emergency care. The phenotype framework proposed here is hypothetical, intended to generate prospective research questions, and not a validated basis for individual treatment selection.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"831-838"},"PeriodicalIF":4.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thymectomy in myasthenia gravis: timing and indications. 重症肌无力的胸腺切除术：时机和适应症。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-09-01 Epub Date: 2026-08-24 DOI: 10.1080/14737175.2026.2708826

Nils Erik Gilhus

引用次数: 0

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials. 拉科沙胺治疗神经性疼痛的临床疗效：随机对照试验的系统回顾。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-22 DOI: 10.1080/14737175.2026.2688513

Gurleen Kaur, Chander Singh, Maryam Altuhafy, Junad Khan

{"title":"Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.","authors":"Gurleen Kaur, Chander Singh, Maryam Altuhafy, Junad Khan","doi":"10.1080/14737175.2026.2688513","DOIUrl":"10.1080/14737175.2026.2688513","url":null,"abstract":"Introduction: Neuropathic pain is considered the most difficult to manage, with many patients getting inadequate relief from the current pharmacotherapy. While many drugs have been added to the regimen, Lacosamide has emerged as a promising therapeutic option. This systematic review focuses on the efficacy and safety of lacosamide in adult patients with neuropathic pain.Methods: Databases such as PubMed, Embase, Scopus, Web of Science, and Cochrane were searched thoroughly for Randomized Controlled Trials (RCTs) published in English through November 2025. The Cochrane Risk of Bias 2 tool was used to assess the risk of bias in the included studies.Results: Eight RCTs involving 976 participants with different neuropathic pain conditions met the inclusion criteria. Across the included studies, Lacosamide (200-600 mg/day) provided a modest reduction in their pain scores. However, it didn't have much of a positive impact on quality of life, limited function, adverse effects were common, and a high dropout rate was observed in several trials.Conclusion: Lacosamide might provide a modest analgesic benefit across multiple neuropathic conditions. But its extensive, long-term use requires more research to confirm its benefits, particularly the optimum dosing protocols.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"805-815"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions. 儿童肌张力障碍的远程深部脑刺激方案：机遇、挑战和未来方向。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-29 DOI: 10.1080/14737175.2026.2692437

Renato P Munhoz, Ron Reitman, Daniel H Johnston, Marcela Alicia Montiel, George M Ibrahim, Carolina Gorodetsky

{"title":"Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.","authors":"Renato P Munhoz, Ron Reitman, Daniel H Johnston, Marcela Alicia Montiel, George M Ibrahim, Carolina Gorodetsky","doi":"10.1080/14737175.2026.2692437","DOIUrl":"10.1080/14737175.2026.2692437","url":null,"abstract":"Introduction: Deep brain stimulation (DBS) of the globus pallidus internus (GPi) is an established therapy for medically refractory childhood dystonia. Achieving optimal outcomes requires repeated programming by experienced multidisciplinary teams in specialized centers. Geographic distance, travel burden, and access to expertise pose major barriers to families long-term care.Areas covered: This review summarizes literature and clinical experience on remote DBS programming for pediatric dystonia through March 2026 identified using targeted searches of PubMed and Embase. Telemedicine-enabled platforms allow clinicians to adjust stimulation parameters through secure interfaces while conducting real-time video assessments. Feasibility studies and early clinical applications indicate that remote programming is technically achievable, safe, and capable of delivering meaningful therapeutic adjustments without in-person visits. For children, who often require early programming, remote care can reduce travel, minimize disruption to school and family life, and facilitate therapy optimization. Challenges remain, including regulatory requirements, infrastructure needs, and development of standardized pediatric protocols.Expert opinion: Remote DBS programming is a promising strategy to expand access to specialized care for children with dystonia. As telemedicine technologies, digital motor assessments, and neuromodulation platforms advance, remote programming has potential to become an integral component of long-term pediatric DBS management, improving outcomes and easing families' burden.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"765-776"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0